BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma

SUPPLEMENTARY MATERIALS



Supplementry Figure 1: BMI-1 is highly expressed in post-autopsy DIPG tumor tissue from patient with no prior radiation or chemotherapy. Immunoblot analysis of BMI-1 expression in DIPG tumor PBTR-43. (T), tumor, (N) matched normal.



Supplementry Figure 2: *p16*^{INK4A} is not induced upon BMI-1 downregulation in DIPG cells. (A) Immunoblot analysis of p16^{INK4A} expression in HeLa cells (positive control) and in DIPG cells treated with 5 μM of PTC-209 for 72 hrs. **(B)** Treatment of normal primary human foreskin fibroblasts (HFF) with 5 μM PTC-209 for 72 hrs induced *p16*^{INK4A} expression assessed by qPCR. Error bars represent the standard deviation from two independent experiments performed in triplicates.

Supplementry Table 1: Anatomic locations of the matched normal tissue from DIPG patients (PBTR)

Patients	Matched normal tissue location
PBTR-15	Frontal cortex
PBTR-18	Frontal cortex
PBTR-22	Right frontal lobe
PBTR-23	Right cerebellum
PBTR-37	Left frontal lobe
PBTR-38	Right frontal lobe
PBTR-43	Right frontal lobe

Supplementary Table 2: IC_{50} (μM) values of PTC-209 in DIPG cell lines

Cell Lines	IC_{50} (μM)
CCHMC-DIPG-1	3.996
SU-DIPG-XXI	1.927
SU-DIPG-IV	4.505
SU-DIPG-XIII	1.820
CCHMC-DIPG-2	2.551